Products in development

Genmab is developing a pipeline of antibody therapeutics with seven products in clinical development, including two marketed products, and over 20 in-house and partnered pre-clinical programs. Our pipeline currently includes naked antibodies, Antibody Drug Conjugates (ADCs) and bispecific antibodies created from our DuoBody® technology platform.

Product Indication Development Phase Partner
Pre-
clinical
I I/II II III IV  
Daratumumab
Multiple myeloma (MM) III Janssen Biotech
  Natural Killer/T-Cell lymphoma (NKTCL) Nasal Type
     II Janssen Biotech
  Myelodysplastic Syndromes (MDS)


    II Janssen Biotech
  Solid Tumors        I/II Janssen Biotech
Ofatumumab
Cancer
Follicular Lymphoma (FL)

III Novartis
Ofatumumab Autoimmune (subcutaneous formulation) Relapsing multiple sclerosis (RMS) III Novartis
Tisotumab vedotin
Solid cancers
    I/II Seattle Genetics
HuMax-AXL-ADC
Solid cancers        I/II Seattle Genetics
Teprotumumab Graves' orbitopathy II Horizon Pharma
HuMax-TAC-ADC (ADCT-301) Lymphoma
        I ADC Therapeutics 
  Acute myeloid leukemia (AML)

        I ADC Therapeutics
JNJ-61186372 Non-small-cell lung cancer (NSCLC)         I Janssen Biotech
JNJ-63709178
Acute myeloid leukemia         Janssen Biotech
AMG 714
Celiac disease     II  Amgen 
>20 Active Pre-clinical Programs Partnered & proprietary programs: HuMab, HuMab-ADC, DuoBody, DuoBody-ADC & HexaBody®



I
   *Study announced, but first patient not yet dosed


Follicular lymphoma (FL)
Follicular lymphoma (FL)
Follicular lymphoma (FL)